NURS 1873 Exam 1 Questions with Verified Answers Latest Update 2025/2026
Intradermal (ID) injection - Answers -inner forearm/upper back
-max volume 0.1ml
-needle gauge 25-27
-needle length 1/8in-5/8in
-syringe size 1ml
-angle of injection 5-15 degrees
Subcutaneous (SQ) injection - Answers -upper arm, thigh, abdomen
-max volume 1.5mL
-needle gauge 23-27
-3/8in-5/8in needle
-syringe size 1-3ml
-angle of injection 45-90 degrees
Intramuscular (IM) injection - Answers -deltoid(less than 2ml), vastis lateralis(2ml or more),
ventrogluteal (2ml or more)
-needle gauge 18-25
-needle length 5/8in-1.5in
-syringe size 1-5
-angle of injection 90 degrees
proper order for drawing up insulin - Answers -air in nph
-air in regular
-draw up regular
-draw up nph
Diabetes Mellitus (DM) - Answers -A chronic multisystem disease characterized by
hyperglycemia related to abnormal insulin production, impaired insulin use, or both.
-Leading cause of: adult blindness, end-stage renal disease and nontraumatic lower limb
amputations
, Prediabetes - Answers -Increased risk for development of T2DM
-Impaired glucose tolerance (IGT): OGTT = 140 to 199 mg/dl
-IFG= fasting glucose of 100-125 mg/dl
-may have both IGT and IFG
Type 2 diabetes metabolic syndrome - Answers -increases risk for T2DM
-increased glucose levels
-abdominal obesity
-High BP
-High levels of triglycerides
-decreased HDL levels
-3/5 components=diagnosis
A1C Level - Answers -3 month history of glucose control
-6.5% or higher
Fasting blood Glucose (FPG) diagnostic - Answers -level greater than 126 mg/dl
Pancreas - Answers Sites and MOA for T2 drugs:
-sulfonylureas, meglitinides, DPP-4 inhibitors and GLP-1 receptor agonists
-increase insulin production
Adipose Tissue - Answers Sites and MOA for T2 drugs:
-Biguanides and thiazolidinediones
-Increase uptake and use of insulin
-Decrease insulin resistance
Muscle - Answers sites and moa for t2 drugs:
-Biguanides and thiazolidinediones
-Increase uptake and use of insulin
-Decrease insulin resistance
Intradermal (ID) injection - Answers -inner forearm/upper back
-max volume 0.1ml
-needle gauge 25-27
-needle length 1/8in-5/8in
-syringe size 1ml
-angle of injection 5-15 degrees
Subcutaneous (SQ) injection - Answers -upper arm, thigh, abdomen
-max volume 1.5mL
-needle gauge 23-27
-3/8in-5/8in needle
-syringe size 1-3ml
-angle of injection 45-90 degrees
Intramuscular (IM) injection - Answers -deltoid(less than 2ml), vastis lateralis(2ml or more),
ventrogluteal (2ml or more)
-needle gauge 18-25
-needle length 5/8in-1.5in
-syringe size 1-5
-angle of injection 90 degrees
proper order for drawing up insulin - Answers -air in nph
-air in regular
-draw up regular
-draw up nph
Diabetes Mellitus (DM) - Answers -A chronic multisystem disease characterized by
hyperglycemia related to abnormal insulin production, impaired insulin use, or both.
-Leading cause of: adult blindness, end-stage renal disease and nontraumatic lower limb
amputations
, Prediabetes - Answers -Increased risk for development of T2DM
-Impaired glucose tolerance (IGT): OGTT = 140 to 199 mg/dl
-IFG= fasting glucose of 100-125 mg/dl
-may have both IGT and IFG
Type 2 diabetes metabolic syndrome - Answers -increases risk for T2DM
-increased glucose levels
-abdominal obesity
-High BP
-High levels of triglycerides
-decreased HDL levels
-3/5 components=diagnosis
A1C Level - Answers -3 month history of glucose control
-6.5% or higher
Fasting blood Glucose (FPG) diagnostic - Answers -level greater than 126 mg/dl
Pancreas - Answers Sites and MOA for T2 drugs:
-sulfonylureas, meglitinides, DPP-4 inhibitors and GLP-1 receptor agonists
-increase insulin production
Adipose Tissue - Answers Sites and MOA for T2 drugs:
-Biguanides and thiazolidinediones
-Increase uptake and use of insulin
-Decrease insulin resistance
Muscle - Answers sites and moa for t2 drugs:
-Biguanides and thiazolidinediones
-Increase uptake and use of insulin
-Decrease insulin resistance
